title: Intralesional injection of diprospan is effective for infantile hemangioma.
abstract: BACKGROUND
  The use of glucocorticoid in infantile hemangioma has remained the main stream for over 30 years. Intralesional corticosteroids got good effects in small-size hemangioma. Here, we introduce a new compound glucocorticoids preparation, Diprospan. Diprospan 1 mL/ampoule contains betamethasone disodium phosphate 2 mg and betamethasone dipropionate 5 mg. It is the combination of short-acting and long-acting components.
  
  
  METHODS
  From January 2005 to December 2013, 57 children with hemangioma were enrolled into this study. The area of tumor ranged from 1 cm to 60 cm. The average age of them receiving the first treatment was 3.9 months. The compound betamethasone preparation was given directly into the lesion at multiple sites along the edge and in the center of tumor. The dosage ranged from 3.5 mg to 14 mg glucocorticoids. In the follow-up, the treatment could be repeated if the tumor tended to grow again.
  
  
  RESULTS
  Nineteen patients received the treatment once, 35 patients twice, and 3 patients thrice. At the end of follow-up, 80.7% (46/57) of the patients' tumors involuted completely. Moreover, 15.8% (9/57) of the patients' tumors shrank but did not involute completely. Also, 3.5% (2/57) of the patients' tumors showed no obvious change and so switched to systemic propranolol treatment. The adverse effects included local atrophy in 3 patients, local ulcer in 2 patients, and Cushing-like manifestations in 2 patients, all of which recovered in a short period.
  
  
  CONCLUSIONS
  Intralesional compound betamethasone preparation is a feasible choice for the small-size hemangioma. For a few of the patients who had no response to it, other treatments including oral propranolol should be adopted in time.
authors: From the *Departments of Plastic Surgery and †Dermatology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
authors: Si-Ming
authors: SM
authors: Yuan
authors: Min
authors: M
authors: Zhang
authors: Yao
authors: Y
authors: Guo
authors: Lei
authors: L
authors: Cui
authors: Zhi-Jian
authors: ZJ
authors: Hong
authors: Hui-Qing
authors: HQ
authors: Jiang
mesh_terms: D001623:Betamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage*; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006391:Hemangioma / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D015552:Injections, Intralesional; D008297:Male; D011433:Propranolol / Q000627:therapeutic use; D012074:Remission Induction; D012878:Skin Neoplasms / Q000188:drug therapy; D012983:Soft Tissue Neoplasms / Q000188:drug therapy; D060726:Torso; D034941:Upper Extremity
chemical_list: D004338:Drug Combinations; D005938:Glucocorticoids; C032812:betamethasone dipropionate, betamethasone sodium phosphate drug combination; D001623:Betamethasone; D011433:Propranolol